3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
113
Neoplasms
8
HER2-positive Breast Cancer
8
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Inflammatory Breast Neoplasms
4
Hematologic Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Locally Advanced Breast Cancer
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Early Breast Cancer
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Nivolumab
13
Ipilimumab
10
pembrolizumab
8
cemiplimab
6
Surveys and Questionnaires
6
Biopsy
6
aldesleukin
5
Radiotherapy
5
Interleukin-2
5
Blood Specimen Collection
5
Temozolomide
4
Sirolimus
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Fluorouracil
4
Educational Status
4
Cyclophosphamide
4
sonidegib
3
fludarabine phosphate
3
fludarabine
3
avelumab
3
Vemurafenib
3
Surgical Procedures, Operative
3
Radiation
3
Petrolatum
3
Cetuximab
3
Aminolevulinic Acid
3
trametinib
2
dabrafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Skin Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled